Показаны сообщения с ярлыком venture capital. Показать все сообщения
Показаны сообщения с ярлыком venture capital. Показать все сообщения

понедельник, 10 июля 2017 г.

How Startup Funding Works

A hypothetical startup will get about $15,000 from family and friends, about $200,000 from an angel investor three months later, and about $2 Million from a VC another six months later. If all goes well. See how funding works in this infographic:


First, let’s figure out why we are talking about funding as something you need to do. This is not a given. The opposite of funding is “bootstrapping,” the process of funding a startup through your own savings. There are a few companies that bootstrapped for a while until taking investment, like MailChimp and AirBnB.
If you know the basics of how funding works, skim to the end. In this article I am giving the easiest to understand explanation of the process. Let’s start with the basics.
Every time you get funding, you give up a piece of your company. The more funding you get, the more company you give up. That ‘piece of company’ is ‘equity.’ Everyone you give it to becomes a co-owner of your company.

Splitting the Pie

The basic idea behind equity is the splitting of a pie. When you start something, your pie is really small. You have a 100% of a really small, bite-size pie. When you take outside investment and your company grows, your pie becomes bigger. Your slice of the bigger pie will be bigger than your initial bite-size pie.
When Google went public, Larry and Sergey had about 15% of the pie, each. But that 15% was a small slice of a really big pie.

Funding Stages

Let’s look at how a hypothetical startup would get funding.

Idea stage

At first it is just you. You are pretty brilliant, and out of the many ideas you have had, you finally decide that this is the one. You start working on it. The moment you started working, you started creating value. That value will translate into equity later, but since you own 100% of it now, and you are the only person in your still unregistered company, you are not even thinking about equity yet.

Co-Founder Stage

 As you start to transform your idea into a physical prototype you realize that it is taking you longer (it almost always does.) You know you could really use another person’s skills. So you look for a co-founder. You find someone who is both enthusiastic and smart. You work together for a couple of days on your idea, and you see that she is adding a lot of value. So you offer them to become a co-founder. But you can’t pay her any money (and if you could, she would become an employee, not a co-founder), so you offer equity in exchange for work (sweat equity.) But how much should you give? 20% – too little? 40%? After all it is YOUR idea that even made this startup happen. But then you realize that your startup is worth practically nothing at this point, and your co-founder is taking a huge risk on it. You also realize that since she will do half of the work, she should get the same as you – 50%. Otherwise, she might be less motivated than you. A true partnership is based on respect. Respect is based on fairness. Anything less than fairness will fall apart eventually. And you want this thing to last. So you give your co-founder 50%.
Soon you realize that the two of you have been eating Ramen noodles three times a day. You need funding. You would prefer to go straight to a VC, but so far you don’t think you have enough of a working product to show, so you start looking at other options.
The Family and Friends Round: You think of putting an ad in the newspaper saying, “Startup investment opportunity.” But your lawyer friend tells you that would violate securities laws. Now you are a “private company,” and asking for money from “the public,” that is people you don’t know would be a “public solicitation,” which is illegal for private companies. So who can you take money from?
  1. Accredited investors – People who either have $1 Million in the bank or make $200,000 annually. They are the “sophisticated investors” – that is people who the government thinks are smart enough to decide whether to invest in an ultra-risky company, like yours. What if you don’t know anyone with $1 Million? You are in luck, because there is an exception – friends and family.
  2. Family and Friends – Even if your family and friends are not as rich as an investor,  you can still accept their cash. That is what you decide to do, since your co-founder has a rich uncle. You give him 5% of the company in exchange for $15,000 cash. Now you can afford room and ramen for another 6 months while building your prototype.

Registering the Company

To give uncle the 5%, you registered the company, either though an online service like LegalZoom ($400), or through a lawyer friend (0$-$2,000). You issued some common stock, gave 5% to uncle and set aside 20% for your future employees – that is the ‘option pool.’ (You did this because 1. Future investors will want an option pool;, 2. That stock is safe from you and your co-founders doing anything with it.)

The Angel Round

With uncle’s cash in pocket and 6 months before it runs out, you realize that you need to start looking for your next funding source right now. If you run out of money, your startup dies. So you look at the options:
  1. Incubators, accelerators, and “excubators” – these places often provide cash, working space, and advisors. The cash is tight – about $25,000 (for 5 to 10% of the company.) Some advisors are better than cash, like Paul Graham at Y Combinator.
  2. Angels – in 2013 (Q1) the average angel round was $600,000 (from the HALO report). That’s the good news. The bad news is that angels were giving that money to companies that they valued at $2.5 million. So, now you have to ask if you are worth $2.5 million. How do you know? Make your best case.  Let’s say it is still early days for you, and your working prototype is not that far along. You find an angel who looks at what you have and thinks that it is worth $1 million. He agrees to invest $200,000.
Now let’s count what percentage of the company you will give to the angel. Not 20%. We have to add the ‘pre-money valuation’ (how much the company is worth before new money comes in) and the investment
$1,000,000 + $200,000=              $1,200,000  post-money valuation
(Think of it like this, first you take the money, then you give the shares. If you gave the shares before you added the angel’s investment, you would be dividing what was there before the angel joined. )
Now divide the investment by the post-money valuation $200,000/$1,200,000=1/6= 16.7%
The angel gets 16.7% of the company, or 1/6.

How Funding Works – Cutting the Pie

What about you, your co-founder and uncle? How much do you have left? All of your stakes will be diluted by 1/6. (See the infographic.)
Is dilution bad? No, because your pie is getting bigger with each investment. But, yes, dilution is bad, because you are losing control of your company. So what should you do? Take investment only when it is necessary. Only take money from people you respect. (There are other ways, like buying shares back from employees or the public, but that is further down the road.)

Venture Capital Round

Finally, you have built your first version and you have traction with users. You approach VCs. How much can VCs give you?   They invest north of $500,000. Let’s say the VC values what you have now at $4 million. Again, that is your pre-money valuation. He says he wants to invest $2 Million. The math is the same as in the angel round. The VC gets 33.3% of your company. Now it’s his company, too, though.
Your first VC round is your series A. Now you can go on to have series B,C – at some point either of the three things will happen to you. Either you will run out of funding and no one will want to invest, so you die. Or, you get enough funding to build something a bigger company wants to buy, and they acquire you. Or, you do so well that, after many rounds of funding, you decide to go public.

Why Companies Go Public?

There are two basic reasons. Technically an IPO is just another way to raise money, but this time from millions of regular people. Through an IPO a company can sell stocks on the stock market and anyone can buy them. Since anyone can buy you can likely sell a lot of stock right away rather than go to individual investors and ask them to invest. So it sounds like an easier way to get money.
There is another reason to IPO. All those people who have invested in your company so far, including you, are holding the so-called ‘restricted stock’ – basically this is stock that you can’t simply go and sell for cash. Why? Because this is stock of a company that has not been so-to-say “verified by the government,” which is what the IPO process does. Unless the government sees your IPO paperwork, you might as well be selling snake oil, for all people know. So, the government thinks it is not safe to let regular people to invest in such companies. (Of course, that automatically precludes the poor from making high-return investments. But that is another story.) The people who have invested so far want to finally convert or sell their restricted stock and get cash or unrestricted stock, which is almost as good as cash. This is a liquidity event – when what you have becomes easily convertible into cash.
There is another group of people that really want you to IPO. The investment bankers, like Goldman Sachs and Morgan Stanley, to name the most famous ones. They will give you a call and ask to be your lead underwriter – the bank that prepares your IPO paperwork and calls up wealthy clients to sell them your stock.  Why are the bankers so eager? Because they get 7% of all the money you raise in the IPO. In this infographic your startup raised $235,000,000 in the IPO – 7% of that is about $16.5 million (for two or three weeks of work for a team of 12 bankers). As you see, it is a win-win for all.

Being an Early Employee at a Startup

Last but not least, some of your “sweat equity” investors were the early employees who took stock in exchange for working at low salaries and living with the risk that your startup might fold. At the IPO it is their cash-out day.
Inspired by: How to Fund a Startup, Paul Graham

воскресенье, 26 февраля 2017 г.

These are the industries attracting the most venture capital


In terms of global venture capital investment, the United States leads the way


Venture capital - the money provided by investors to startup firms and small businesses showing potential for long-term growth – is generally thought of as “good capital”.
It promotes innovation and long-term investment, but not all industries manage to attract enough of it.
Industry investment
In terms of global venture capital investment, the United States is leading the way-with an estimated $58.8 billion invested across the country in 2015.
The chart below shows the top 10 industries that are attracting the most venture capital investment:


Software investment accounts for 36.2% of US VC funding, while biotechnology comes second with 17.3%. Media and entertainment rounds off the top three with 9.5%.
Other areas of growth and innovation include information technology services, medical devices and equipment and industrial energy.
Lower levels of investment are in financial services, consumer products and telecommunications.
Growth of technology
With the dawn of the Fourth Industrial Revolution heralding an ever-greater use of technology, it is no surprise that much VC investment goes to software companies. In the second quarter of 2016, the value of VC investments in the US software industry amounted to approximately $8.74 billion dollars.



Phone- based apps are some of the most valuable start-ups in the world with many using VC funding to enable global expansion.



понедельник, 23 января 2017 г.

Where the money is, 2016 edition: The top 100 VCs investing in biotech, by the numbers

Using the lat­est set of num­bers on the top 100 VCs op­er­at­ing in the US, you can sketch out all of the big trends at play in the multi­bil­lion-dol­lar game of biotech in­vest­ing and star­tups.

David Mott, NEA

The top four VCs — Flag­ship, Third Rock, New En­ter­prise As­so­ci­ates and Arch Ven­ture — all en­tered 2016 flush with cash and ready to start ramp­ing up new com­pa­nies while fos­ter­ing the up­starts al­ready in their port­fo­lios, ac­cord­ing to fig­ures Thom­son Reuters pro­vided to End­points News. NEA may have slipped down the list a bit, but the life sci­ences group under David Mott con­tin­ues to be one of the most pro­lific in the in­dus­try, not shy in the least to take a lead role in big new rounds.
In many cases, these four VCs have been kick­start­ing com­pa­nies into ex­is­tence using a blank-slate ap­proach in track­ing down and spark­ing the shift from acad­e­mia into the clinic. And groups like Atlas and 5AM have been close be­hind.
If you ranked these firms by the num­ber of deals, Po­laris would come in at the top (same as last year) though they are clearly look­ing at mak­ing smaller bets across a wider slate of can­di­dates.


Third Rock Ven­tures

Most of these top play­ers are keenly in­ter­ested in the ear­li­est stages of in­vest­ing in biotech, but the un­der­tow on the money is also in­evitably broad­en­ing to in­clude later stages of work, which is why Flag­ship re­cently added a new $285 mil­lion fund to ex­tend its reach fur­ther down the clinic.
With IPOs suf­fer­ing last year, it’s also no sur­prise to see a crossover in­vestor like RA Cap­i­tal drop from 5th in 2015 to 56th in 2016. But Or­biMed and Deer­field re­main in the top tier of the busiest play­ers.
The num­ber of new deals has slipped, which is also no sur­prise. 2015 re­mains a record year in ven­ture in­vest­ing that will be hard to beat in the com­ing years, as VCs wait out the lull in the pub­lic mar­ket. But the over­all flow of cash re­mains near enough to his­toric highs to keep the land­scape look­ing bright.
To fully un­der­stand these num­bers, you have to start by clar­i­fy­ing that the to­tals in the amount in­vested col­umn aren’t gospel. Thom­son Reuters gath­ers up all the num­bers it can find — in the news, SEC fil­ings and so on — and then divvies the amount of each round by the num­ber of play­ers on record. If one VC was in­volved in a round, they have a solid fig­ure. If 4 or 5 play­ers are in­volved, they di­vide by the total and use that as the av­er­age. It’s not per­fect, but it does cap­ture the level of ac­tiv­ity each VC is play­ing with.


Po­laris Part­ners

Based on the num­ber of new funds that con­tinue to at­tract record amounts of money for play­ers like Ver­sant, it’s fair to say that 2017 looks solid as we begin the year. Just about every­one ex­pects a re­peat of 2016 on the IPO front, though with Don­ald Trump en­ter­ing the White House as the wild card in Amer­i­can pol­i­tics — stroking cor­po­ra­tions with one hand while slap­ping pharma with the other — who re­ally knows what’s going to hap­pen?
Some­one asked me re­cently where they had the best shot at rais­ing cash for his biotech ven­ture. My sug­ges­tion: Look over the num­bers and deals in your own sec­tor and see who has a track record in your field. And this is a good place to get started on that ex­er­cise.


Table
Top 100 VC firms in­vest­ing in U.S. biotech com­pa­nies
Based on all known 2016 deals

Firm
# Deals
# of Com­pa­nies
Avg Eq­uity/Deal ($M)
Avg Eq­uity/Com­pany ($M)
Total Eq­uity In­vested
1
12
9
21.82
29.09
261.83
2
14
11
12.18
15.51
170.57
3
22
21
6.64
6.96
146.11
4
17
15
7.72
8.75
131.18
5
10
8
11.88
14.85
118.78
6
14
14
8.25
8.25
115.51
7
15
14
6.99
7.48
104.79
8
13
13
7.11
7.11
92.42
9
1
1
92.00
92.00
92.00
10
21
15
4.31
6.03
90.47
11
5
5
16.79
16.79
83.95
12
8
7
10.33
11.80
82.63
13
4
4
19.98
19.98
79.93
14
20
17
4.00
4.70
79.90
15
23
21
3.30
3.61
75.82
16
14
12
4.83
5.63
67.56
17
3
3
22.14
22.14
66.42
18
5
4
12.40
15.50
62.01
19
1
1
61.45
61.45
61.45
20
1
1
55.00
55.00
55.00
21
7
7
7.60
7.60
53.19
22
10
10
5.17
5.17
51.68
23
13
11
3.86
4.57
50.23
24
7
7
7.17
7.17
50.17
25
6
6
8.30
8.30
49.81
26
4
4
12.23
12.23
48.91
27
1
1
48.00
48.00
48.00
28
9
8
5.21
5.86
46.90
29
7
6
6.54
7.63
45.80
30
2
2
21.95
21.95
43.91
31
12
12
3.53
3.53
42.33
32
4
4
10.38
10.38
41.51
33
7
7
5.66
5.66
39.61
34
2
2
19.75
19.75
39.50
35
9
8
4.21
4.74
37.93
36
8
7
4.72
5.40
37.77
37
3
3
12.18
12.18
36.53
38
8
8
4.34
4.34
34.72
39
6
5
5.55
6.66
33.31
40
2
2
16.50
16.50
33.00
41
7
7
4.67
4.67
32.72
42
1
1
32.33
32.33
32.33
43
4
4
7.93
7.93
31.71
44
8
8
3.90
3.90
31.21
45
10
9
3.01
3.34
30.05
46
4
4
7.44
7.44
29.75
47
10
9
2.97
3.30
29.66
48
9
9
3.25
3.25
29.28
49
5
5
5.54
5.54
27.70
50
5
4
5.54
6.93
27.70
51
2
2
13.46
13.46
26.92
52
2
2
13.40
13.40
26.80
53
2
2
13.04
13.04
26.07
54
3
3
8.17
8.17
24.51
55
4
4
6.11
6.11
24.45
56
6
6
3.86
3.86
23.19
57
4
4
5.70
5.70
22.79
58
6
5
3.78
4.54
22.69
59
10
9
2.20
2.44
21.98
60
3
3
7.27
7.27
21.80
61
5
5
4.35
4.35
21.73
62
4
3
5.17
6.89
20.68
63
2
2
10.31
10.31
20.63
64
2
2
10.06
10.06
20.13
65
3
3
6.71
6.71
20.12
66
7
5
2.85
3.99
19.96
67
6
6
3.27
3.27
19.63
68
4
4
4.82
4.82
19.28
69
6
6
3.13
3.13
18.76
70
2
2
9.31
9.31
18.61
71
6
6
3.08
3.08
18.47
72
3
3
6.15
6.15
18.46
73
2
2
9.21
9.21
18.42
74
1
1
18.31
18.31
18.31
75
5
5
3.53
3.53
17.64
76
3
3
5.66
5.66
16.98
77
3
3
5.66
5.66
16.98
78
4
3
4.04
5.39
16.16
79
2
1
8.04
16.09
16.09
80
2
2
7.95
7.95
15.90
81
2
2
7.94
7.94
15.88
82
2
2
7.86
7.86
15.72
83
2
2
7.84
7.84
15.68
84
2
2
7.63
7.63
15.25
85
3
3
4.95
4.95
14.85
86
2
2
7.23
7.23
14.46
87
1
1
14.35
14.35
14.35
88
3
3
4.72
4.72
14.16
89
2
2
7.06
7.06
14.11
90
2
2
6.92
6.92
13.83
91
1
1
13.75
13.75
13.75
92
1
1
13.75
13.75
13.75
93
4
4
3.42
3.42
13.68
94
2
2
6.79
6.79
13.57
95
3
3
4.52
4.52
13.55
96
2
2
6.65
6.65
13.30
97
3
3
4.43
4.43
13.29
98
2
2
6.62
6.62
13.24
99
1
1
13.05
13.05
13.05
100
4
3
3.23
4.31
12.93